Recurrent DVT During Therapeutic Apixaban (Eliquis)
A new DVT occurring during therapeutic anticoagulation should be treated as anticoagulation “failure,” which requires confirmation of adherence and drug interactions, then escalation/change of anticoagulant therapy. [1] For patients who develop a VTE event while on a DOAC (including apixaban), switching to low-molecular-weight heparin (LMWH) is recommended. [1]
Confirmation of Recurrent VTE and Treatment Failure
New imaging should be obtained and compared with prior studies to confirm a true recurrent acute event. [1] Anticoagulant levels should be checked in patients presenting with acute VTE despite ongoing anticoagulation, using an assay calibrated for the specific DOAC. [1] Medication nonadherence is the most significant cause of apparent “treatment failure” and should be assessed during the evaluation. [1]
Anticoagulant Level and Adherence Assessment
Anti-Xa activity level (calibrated specifically for apixaban) should be checked in patients on apixaban with recurrent VTE. [1] Adherence and medication administration timing should be reviewed, including correct food requirements and interactions that may reduce DOAC exposure. [2]
Anticoagulant Selection After DOAC Breakthrough Event
For patients who develop a VTE event while on warfarin or a DOAC, switching to LMWH for at least ~1 month while assessing for cancer is recommended. [1] If bleeding risk prohibits anticoagulant escalation/change, a temporary IVC filter can be considered as a last option. [1]
LMWH Strategy After Breakthrough Event
For patients who develop recurrent VTE while already receiving LMWH, an LMWH dose increase of about one-quarter to one-third is recommended. [1] Once-daily LMWH regimens are generally changed to twice-daily dosing when intensifying therapy. [1]
Reversible Causes to Evaluate During the Same Episode
New interacting medications should be identified and discontinued when possible because drug interactions can reduce anticoagulant effectiveness. [1] Correct DOAC dosing regimen and administration should be confirmed because incorrect dosing contributes to apparent treatment failure. [2]
Diagnostic Workup for Predisposing Conditions
A hematology consultation is recommended for recurrent VTE events to discuss thrombophilia and duration/strategy of anticoagulation. [1] Testing should include evaluation for antiphospholipid antibody syndrome when recurrent VTE occurs. [1] Cancer evaluation should be performed as clinically indicated because cancer and other acquired hypercoagulable states are associated with recurrent VTE and anticoagulation failure. [1]
Practical Care Coordination Steps
Inpatient hematology consultation should be obtained for patients with significant anticoagulation concerns. [1] Outpatient hematology follow-up should be arranged after discharge for recurrent VTE events to plan long-term anticoagulation strategy. [1]
Targeted Summary of the Immediate Action
Immediate management after confirmed DVT recurrence on apixaban should include verification of true recurrence and apixaban exposure, then switching from apixaban to LMWH for at least ~1 month. [1] If intensification is not feasible due to bleeding risk, temporary IVC filter placement may be considered as a last option. [1]